{"product_id":"amgn-ansoff-analysis","title":"(AMGN) Amgen Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Amgen Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification in a concise, actionable framework for strategy, investing, or planning. The page includes a real preview\/sample so you can review style and substance before buying. Purchase the full version to access the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnbrel franchise defense in inflammatory disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnbrel, used for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, remains a mature-share defense play for Amgen Inc. In 2025, Enbrel revenue was about $3.7 billion, so protecting long-time rheumatology and dermatology prescribers is the key move. This is retention, not expansion, in a crowded inflammatory-disease market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProlia and Xgeva bone-health share expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlia treats postmenopausal osteoporosis, while Xgeva helps prevent skeletal-related complications, so both target the same bone-health specialist base. In Amgen’s FY2025 mix, this franchise still anchors a multibillion-dollar category, with Prolia and Xgeva together above $6B in annual sales. Focused promotion in osteoporosis and oncology-supportive care can lift share without new channels, since one prescriber base can use both brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepatha uptake in cardiovascular prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepatha supports market penetration in a mature cardiology field: in FOURIER, it cut major cardiovascular events by 15% and myocardial infarction by 27%. Amgen reported Repatha sales of about $1.6 billion in 2024, showing room to grow share. More specialist adoption and payer access can lift use in secondary prevention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupportive-care oncology franchise reinforcement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen Inc. deepens market penetration in supportive-care oncology by keeping Neulasta, Neupogen, Aranesp, Epogen, and Nplate embedded in established physician, clinic, hospital, and dialysis accounts. This matters in a business that still depends on high-volume, repeat use: Amgen reported $33.4 billion in 2024 revenue, with biosimilar and mature-franchise pressure making account retention more important.\u003c\/p\u003e\n\u003cp\u003eThese products address infection risk, anemia, and low platelet needs during cancer treatment, so the play is to win more share inside existing sites of care rather than open new demand pools. The one-line view: protect the base, raise account stickiness, and defend pricing where clinical trust already exists.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocuses on existing supportive-care accounts\u003c\/li\u003e\n\u003cli\u003eCovers infection, anemia, platelet needs\u003c\/li\u003e\n\u003cli\u003eUses recurring physician and hospital demand\u003c\/li\u003e\n\u003cli\u003eSupports share defense in mature franchises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty-channel distribution intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen’s specialty-channel distribution is dense: it sells through wholesale distributors and directly to physicians, clinics, dialysis centers, hospitals, and pharmacies, using the same routes that already support its core medicines. In 2025, Amgen reported $34.1 billion in net sales, and tighter channel coverage helps lift access and repeat use of current products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader reach boosts patient access\u003c\/li\u003e\n\u003cli\u003eDirect sites support repeat dispensing\u003c\/li\u003e\n\u003cli\u003e2025 sales: $34.1 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen Wins by Defending Franchises, Not Chasing New Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc. drives market penetration by defending entrenched franchises in existing specialist channels, not by chasing new demand. In FY2025, total sales were $34.1 billion, with Enbrel at about $3.7 billion and Repatha near $1.6 billion, showing the value of repeat use and payer access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel\u003c\/td\u003e\n\u003ctd\u003e$3.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany sales\u003c\/td\u003e\n\u003ctd\u003e$34.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Amgen Inc.’s growth strategy across market penetration, market development, product development, and diversification\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, structured Ansoff Matrix for Amgen Inc., helping teams simplify growth strategy decisions across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, reputable Amgen sources to validate and trace each Ansoff growth path, speeding due diligence and making strategic assumptions defensible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorldwide commercialization footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen sells therapies in more than 100 countries, so the same products can enter new payers and reimbursement systems without a new product launch. In 2025, its revenue was about $33 billion, showing the scale of this global base. That footprint makes market development the clearest Ansoff lever for Amgen Inc. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led geographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen Inc. uses partner-led expansion to move existing programs into new countries and customer groups without building every market alone. Deals with Novartis, UCB, Bayer HealthCare, BeiGene, and Eli Lilly can speed access, share launch costs, and widen reach for assets with global demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale-plus-direct access expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen Inc. uses wholesale distributors and direct-to-consumer access, so its brands can reach more than provider-only channels. That wider route fits market development by opening existing therapies to new buyer groups and care settings. With about $33.4 billion in 2024 revenue, even small access gains can scale fast across its large portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiosimilar rollout into additional payer markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen Inc.’s biosimilar set, AMJEVITA, MVASI, KANJINTI, and AVSOLA, gives it a clear path into price-sensitive payer markets. These products fit hospitals, PBMs, and formulary-led systems because they use known molecules with lower-cost access points. That makes the rollout a direct way to enter new segments without building new drug brands from scratch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKnown molecules lower adoption friction\u003c\/li\u003e\n\u003cli\u003eFormulary access drives payer entry\u003c\/li\u003e\n\u003cli\u003ePrice pressure favors biosimilar scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDialysis and hospital channel expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen already sells Parsabiv and anemia therapies into dialysis centers and hospitals, so pushing these brands deeper into those channels is direct market development. The U.S. has more than 550,000 dialysis patients, and these sites buy through tight formularies, so even small gains in placement can scale fast. Amgen reported $33.4 billion in 2024 revenue, showing the base to support this push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing brands in new sites\u003c\/li\u003e\n\u003cli\u003eTaps large, specialized buyers\u003c\/li\u003e\n\u003cli\u003eRaises share without new molecules\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen’s Growth Engine: Global Access and Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.'s market development is mainly global rollout of existing drugs into new payers, countries, and care settings. FY2025 revenue was about $33.0 billion, so even small access gains can matter fast.\u003c\/p\u003e\n\u003cp\u003ePartner deals and biosimilars like AMJEVITA and MVASI help Amgen Inc. enter price-sensitive markets without new R\u0026amp;D-heavy launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$33.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAmgen Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKHK4083 for atopic dermatitis and autoimmune disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen and Kyowa Kirin are co-developing KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for atopic dermatitis and other autoimmune diseases, so this is a new product for an existing specialty market.\u003c\/p\u003e\n\u003cp\u003eAtopic dermatitis affects about 10% of adults and 20% of children worldwide, and the global eczema market was valued at about $16 billion in 2024, which shows the size of the launch pool.\u003c\/p\u003e\n\u003cp\u003eFor Amgen, this fits product development in the Ansoff Matrix by adding a differentiated immunology asset to a market it already serves through specialty care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSotorasib combination development in KRAS G12C NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen is extending Lumakras (sotorasib) in KRAS G12C-mutant NSCLC by testing it with VS-6766, a classic product-development move in oncology. This matters because NSCLC makes up about 85% of lung cancers, and combo trials aim to push beyond the modest single-agent gains seen with KRAS G12C drugs. The strategy reuses an existing asset and can deepen the market without starting from zero.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOtezla indication expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOtezla’s expansion into oral ulcers linked to Behçet's disease is a product development move: it adds a new labeled use to an already approved immunology brand in the same inflammatory market. Amgen can extend an established asset beyond plaque psoriasis and psoriatic arthritis without building a new drug from scratch. That keeps development risk lower while widening reach in a niche with limited treatment options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuroscience pipeline via Neumora and Plexium\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen uses its R\u0026amp;D ties with Neumora Therapeutics and Plexium as a product-development bet in neuroscience, aimed at adding new candidates before they reach the commercial portfolio. This fits Ansoff’s product-development path: new science, same enterprise base. Amgen reported $33.4 billion in 2024 revenue, so outside discovery helps widen its future launch pool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNeuroscience discovery via partners\u003c\/li\u003e\n\u003cli\u003eBuilds future pipeline, not current sales\u003c\/li\u003e\n\u003cli\u003eSupports Amgen’s product-development strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNewer branded biologics portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen Inc.'s newer branded biologics portfolio shows product development in action: EVENITY, Aimovig, BLINCYTO, KYPROLIS, and Corlanor extend the Company beyond legacy brands into specialty care. In 2025, Amgen reported about $34.1 billion in revenue, and this mix helps widen its growth base across bone health, migraine, oncology, and cardiovascular care. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunches new biologics in higher-value specialty markets\u003c\/li\u003e\n\u003cli\u003eReduces dependence on older legacy products\u003c\/li\u003e\n\u003cli\u003eUses innovation to support revenue growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen Expands Specialty Care With New Uses and Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen’s product development centers on extending existing science into new uses and assets: KHK4083 for atopic dermatitis, Lumakras combos in KRAS G12C NSCLC, and Otezla in Behçet’s oral ulcers. In 2025, Amgen reported about $34.1 billion in revenue, and these moves help widen its specialty-care base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKHK4083\u003c\/td\u003e\n\u003ctd\u003eNew asset\u003c\/td\u003e\n\u003ctd\u003ePhase 3-ready\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLumakras combo\u003c\/td\u003e\n\u003ctd\u003eNew use\u003c\/td\u003e\n\u003ctd\u003eNSCLC is ~85% of lung cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOtezla label\u003c\/td\u003e\n\u003ctd\u003eNew indication\u003c\/td\u003e\n\u003ctd\u003eBehçet's oral ulcers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars platform beyond originator biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen Inc. has four key biosimilars in this lane: AMJEVITA, MVASI, KANJINTI, and AVSOLA. That shifts the company from originator-biologic pricing to a lower-margin, higher-volume model, where win rates depend on payer access and rebate pressure. It also expands Amgen Inc. into a broader, more price-sensitive market segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroscience market entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.'s Aimovig is a clear diversification move into neuroscience: it entered migraine, a market far from Amgen Inc.'s core oncology and inflammation businesses. In 2025, migraine still affected about 1 in 6 U.S. adults, so the category offered a large new pool beyond Amgen Inc.'s legacy franchises. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular outcomes market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepatha’s 2024 sales were about $2.0 billion, showing Amgen can win in large-scale cardiovascular prevention, not just oncology-supportive care. The PCSK9 inhibitor reached a broader LDL-C management market, with lower LDL linked to fewer major adverse cardiovascular events. That move widens Amgen’s addressable market and reduces dependence on its legacy base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNephrology and mineral metabolism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eParsabiv and Sensipar\/Mimpara tie Amgen to dialysis care by treating calcium and parathyroid disorders in chronic kidney disease. This is diversification into a distinct specialty market with over 500,000 U.S. patients on dialysis, where treatment is closely linked to nephrology workflows.\u003c\/p\u003e\n\u003cp\u003eAmgen’s renal care franchise also adds repeat use and specialist access, not just one-off prescriptions. In 2024, Amgen reported $33.4 billion in total revenue, so even niche renal products can support scale and cross-sell depth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets dialysis and nephrology clinics\u003c\/li\u003e\n\u003cli\u003eServes CKD mineral metabolism needs\u003c\/li\u003e\n\u003cli\u003eReaches a large, chronic patient base\u003c\/li\u003e\n\u003cli\u003eAdds specialty-market diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital health-enabled partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen Inc.’s partnership with Datos Health adds a digital layer to its model, so the company is not just selling therapies but also helping support care delivery around them. That fits Ansoff diversification because it opens a new service path beside core pharma commercialization. In 2025, this kind of model matters more as Amgen keeps broadening beyond pure drug sales in a market where the company already generates tens of billions in annual revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves Amgen beyond manufacturing\u003c\/li\u003e\n\u003cli\u003eAdds digital support to therapies\u003c\/li\u003e\n\u003cli\u003eDeepens patient and provider engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen Diversifies Beyond Biologics With Growth Across Key Specialty Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen Inc.’s diversification extends beyond core biologics into biosimilars, migraine, cardiovascular prevention, and renal care, widening revenue sources and reducing dependence on legacy franchises. Repatha reached about $2.0 billion in 2024 sales, and Amgen Inc. reported $33.4 billion in total revenue in 2024. The mix also adds lower-margin but higher-volume access in competitive specialty markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003eAMJEVITA, MVASI, KANJINTI, AVSOLA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuroscience\u003c\/td\u003e\n\u003ctd\u003eAimovig in migraine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardio\u003c\/td\u003e\n\u003ctd\u003eRepatha, $2.0B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenal\u003c\/td\u003e\n\u003ctd\u003eParsabiv, Sensipar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191843430665,"sku":"amgn-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/amgn-ansoff-analysis.webp?v=1783678670","url":"https:\/\/dcfanalyst.com\/products\/amgn-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}